Synth-a-Freeze CTS media is optimally formulated without antibiotics, antimycotics, hormones, growth factors, serum, or protein and buffered with HEPES and sodium bicarbonate.

Use for cryopreserving a variety of primary and stem cells:

 Save time and effort with 4 degree stable storage of thawed media and compatibility with a variety freezing protocols
 Be ready for clinical research with this cGmP manufactured, chemically defined, protein-free formula

Cryopreserve a Variety of Cell Types:
Cell Therapy Systems Synth-a-Freeze CTS media performs comparable to our standard, serum-containing cryopreservation medium for cryopreserving a variety of cell types including human Embryonic Stem Cells, Neural Stem Cells (Ref 1), Mesenchymal Stem Cells and Keratinocytes (Ref 2). We do not recommend using Synth-a-Freeze media for cryopreservation of human epidermal melanocytes.

Simple Incorporation into Your Current Freezing Protocol:
Synth-a-Freeze CTS media can be used with any standard freezing protocol. Just add thawed Cell Therapy Systems Synth-a-Freeze CTS media to detached and pelleted cells, aliquot, and freeze. For optimal results, the use of a controlled-rate freezer is recommended.

Simplify Your Transition into Clinical Research:
The Gibco Cell Therapy Systems (CTS) brand offers a broad array of products for use in cell therapy applications, including media, reagents, growth factors, enzymes, cell selection/expansion reagents, and devices. Gibco Cell Therapy Systems (CTS) products deliver:
 Reduced burden in qualifying reagents
 Included appropriate certificates of analyses and origin
 Convenient access to our Drug Master File (DMF)

For Research Use or Manufacturing of Cell, Gene, or Tissue-Based Products.

CAUTION: Not intended for direct administration into humans or animals

References:
 S. Shin and M. Vemuri. Culture and Differentiation of Human Neural Stem Cells. L.C. Doering (ed). Protocols for Neural Cell Culture. Springer Protocol Handbooks.
 S. Lemaire, K. Kosowska-Shick, P. Appelbaum, G. Verween, P. Tulkens, and F. Van Bambeke. Cellular Pharmacodynamics of the Novel Biaryloxazolidinone Radezolid: Studies with Infected Phagocytic and Nonphagocytic cells, Using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob Agents Chemother 54(6) 2010: 2549-2559.